ПЕЧЕНОЧНО-ЛЕГОЧНЫЙ СИНДРОМ: ВОПРОСЫ ПАТОГЕНЕЗА, ДИАГНОСТИКИ И ЛЕЧЕНИЯ


Цитировать

Полный текст

Аннотация

В основе печеночно-легочного синдрома (ПЛС,) развивающегося у пациентов с хроническими заболеваниями печени, лежит внутрилегочная вазодилатация, нарушающая артериальную оксигенацию. Рассматриваются вопросы патофизиологии, диагностики и лечения данной патологии. Для диагностики ПЛС достаточно таких методов, как контрастная эхокардиография и стандартный кардиопульмональный тест. Лечение данного состояния заключается в терапии кислородом и решении вопроса о проведении ортотопической трансплантации печени, особенно при выраженной гипоксемии.

Об авторах

И Е Байкова

Кафедра госпитальной терапии № 2 лечебного факультета ГОУ ВПО РГМУ, Москва

Кафедра госпитальной терапии № 2 лечебного факультета ГОУ ВПО РГМУ, Москва

И Г Никитин

Кафедра госпитальной терапии № 2 лечебного факультета ГОУ ВПО РГМУ, Москва

Кафедра госпитальной терапии № 2 лечебного факультета ГОУ ВПО РГМУ, Москва

I E Baikova

I G Nikitin

Список литературы

  1. Schenk P, Schoniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterol 2003;125:1042-52.
  2. Palma D, Fallon M. The hepatopulmonary syndrome. J Hepatology 2006;45:617-25.
  3. Rodrigues-Rosin R, Krowka MJ, Herve P, et al. On behalf of the ERS Task Force Pulmonary-Hepatic Vascular Disorders Scientific Committee ERS Task Force PHD Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004;24:861-80.
  4. Martinez G, Barbera J, Visa J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatology 2001;34:756-58.
  5. Regev A, Yeshurun M, Rodriguez M, et al. Transient hepatopulmonary syndrome in a patient with acute hepatitis A. J Viral Hep 2001;8:83-86.
  6. Teuber G, Teupe C, Dietrich C, et al. Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis. Eur J Intern Med 2002;13:311-18.
  7. Gomez F, Barbera J, Roca J, et al. Effects of nebulized NG-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology 2006;43:1084-91.
  8. Brussino L, Bucca C, Morello M, et al. Effect on dyspnoea and hypoxaemia of inhaled NG-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 2003;362:43-44.
  9. Arguedas MR, Drake BB, Kapoor A, et al. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterol 2005;128:328-33.
  10. Luo B, Liu L, Tang L, et al. ET-1 and TNF-{alpha} in HPS: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats. Am J Physiol Gastrointest Liver Physiol 2004;286:G294-G303.
  11. Zhang J, Ling Y, Luo B, et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterol 2003;125:1441-51.
  12. Luo B, Liu L, Tang L, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol 2003;38:556-63.
  13. Ling Y, Zhang J, Luo B, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of experimental hepatopulmonary syndrome. Hepatology 2004;39:1593-602.
  14. Luo B, Tang L, Wang Z, et al. Cholangiocyte endothelin-1 and transforming growth factor-beta1 production in rat experimental hepatopulmonary syndrome. Gastroenterol 2005;129:682-95.
  15. Sztrymf B, Rabiller A, Nunes H, et al. Prevention of hepatopulmonare syndrome by pentoxifylline in cirrhotic rats. Eur Respir J 2004;23:752-58.
  16. Gomez F, Martinez-Palli G, Barbera J, et al. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology 2004;40:660-66.
  17. Arguedas M, Abrams GA, Krowka MJ, et al. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003;37:192-97.
  18. Abrams G, Nanda N, Dubovsky E, et al. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterol 1998:114.
  19. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observation and lack of therapeutic response to somatostatin analogue. Chest 1993;104:515-21.
  20. Lima BL, Franca AV, Pazin-Filho A, et al. Frequency, clinical characteristics, and respiratory parameters of hepatopulmonary syndrome. Mayo Clin Proc 2004;79-42.
  21. Lee KN, Lee HJ, Shin WW, et al. Hypoxemia and liver cirrhosis (hepatopulmonary syndrome) in eight patients: comparison of the central and peripheral pulmonary vasculature. Radiology 1999;211:549-53.
  22. Katsuta Y, Honma H, Zhang X, et al. Pulmonary blood transit time and impaired arterial oxygenation in patients with chronic liver disease. J Gastroenterol 2005;40:57-63.
  23. Swanson KL, Wiesner RH, Kwowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005;41:1122-29.
  24. Javaheri S, Almoosa KF, Saleh K, et al. Hypocapnia is not a predictor of central sleep apnea in patients with cirrhosis. Am J Respir Crit Care Med 2005;171:908-11.
  25. Martinez-Palli G, Barbera JA, Taura P, et al. Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome. J Hepatol 1999;331:1075-79.
  26. Philit F, Wiesendanger T, Gille D, et al. Late resolution of hepatopulmonary syndrome after liver transplantation. Respiration 1997;6:173-75.
  27. Durand P, Baujard C, Grosse AL. Reversal of hypoxemia by inhaled nitric oxide in children with severe hepatopulmonary syndrome, type 1, during and after liver transplantation. Transplantation 1998;65:437-39.
  28. Sulieman B, Voigt M, Kats D, et al. Data driven policy for points allocation in hepatopulmonary syndrome. Hepatology 2005;42:347.
  29. Henrinon J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003;82:392-406.
  30. Riegler JL, Lang KA, Johnson SP, et al. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterol 1995;109:978-83.
  31. Selim KM, Akriviadis EA, Zuckerman E, et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 1998;93:455-58.
  32. Allgaier HP, Haag K, Ochs A, et al. Hepatopulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol 1995;23:102-105.
  33. Paramesh A, Hussain S, Shneider B, et al. Improvement of hepatopulmonary syndrome after transjugular intrahepatic portosystemic shunting: case report and review of literature. Pediatr Transplant 2003;7:157-62.
  34. Chevallier P, Novelli L, Motamedi JP, et al. Hepatopulmonary syndrome successfully treated with transjugular intrahepatic portosystemic shunt: a three-year follow-up. J Vasc Interv Radiol 2004;15:647-48.
  35. Corley DA, Scharschmidt B, Bass N, et al. Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterol 1997;113:728-31.
  36. Abrams GA, Fallon M. The hepatopulmonary syndrome. Clin Liver Dis 1997;1:185-200.
  37. Abrams GA, Fallon MB. Treatment of hepatopulmonary syndrome with Allium sativum (garlic): a pilot trial. J Clin Gastroenterol 1998;27:232-35.
  38. Brussino L, Bucca C, Morello M, et al. Effect on dyspnoea and hypoxemia of inhaled NG-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 2003;362:43-44.
  39. Anel RM, Sheagren JN. Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents. Clin Infect Dis 2001;32:E131-E136.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2009

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах